Although the coexistence of HS and IgA vasculitis is exceedingly rare, previous reports have implicated biologic agents such as tumor necrosis factor (TNF)-α inhibitors, including adalimumab (5). This evidence concerns the gene TNF and histiocytic sarcoma.